We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Results for
"[search-keyword]"
Sponsor content
20 result(s) found, displaying 1 to 10
-
Australian Public Assessment Report (AusPAR)Brukinsa (zanubritinib) was approved to treat adult patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma, including patients with deletion 17p and/or TP53 mutation.
-
Australian Public Assessment Report (AusPAR)Tevimbra (tislelizumab) has been approved for the treatment of oesophageal squamous cell carcinoma and non-small cell lung cancer.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for TEVIMBRA tislelizumab 100 mg/10 mL concentrated injection vial.
-
Prescription medicine decision summaryTevimbra (tislelizumab) has been approved for the treatment of patients with various types of oesophageal squamous cell carcinoma and non-small cell lung cancer.
-
Jul-2024Prescription medicine evaluationActive ingredient: tislelizumab.
-
-
Apr-2024Prescription medicine evaluationActive ingredient: tislelizumab.
-
-
Oct-2023Prescription medicine evaluationActive ingredient: tislelizumab.
-